- Botulinum toxin achieved high response rates in digital ischemia, ulcers, and gangrene.
- Adverse events were infrequent and mild.
- Supports botulinum toxin as a rescue therapy in refractory cases.
- No clear predictors of response identified.
- Prospective trials are needed for validation.
Source: JAMA Dermatology
